Specialties Medical OncologyQuestion

How would you approach therapy for a SMARCA4-deficient undifferentiated sarcoma with isolated involvement of a mediastinal lymph node?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?

Is there any antiresorptive therapy that you would be comfortable prescribing if the patient refuses to see a dentist for clearance and is at risk of skeletal-related events?

How do you contextualize the stage 1 results from the PRESERVE-003 trial within the current treatment landscape for patients with squamous NSCLC who have progressed on PDL-1 therapy?

Assuming regulatory approval, what role do you foresee for varegacestat (RINGSIDE) in the management of progressive desmoid tumors, particularly in relation to existing systemic treatment options?

How, if at all, has the 7-year CROWN data influenced your approach to treatment duration with lorlatinib in patients with ALK-positive NSCLC who remain progression-free long term?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.